Immunologic Factor
‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult
Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics
Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer
Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology
Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial
Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration
Keytruda around head and neck cancer surgery cuts chance of disease coming back
Keytruda, Head, perioperative, Episodic
Ex-FDA leader joins new initiative designed to fight ‘unfortunate reality’ of vaccine landscape
Vaccines, Project, Misinformation, Initiative, Policy, Intact, Ex-FDA, threat, Recommendation, M.D., reality
Mercks Gardasil sales sink further amid China market pressure
Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China
Versant’s Granite Bio unveils with $100M for new autoimmune disease antibodies
Autoimmune Diseases, granite, GRT-001, Versant, interleukin-3
Novavax’s COVID-19 jab looks to be on track for approval
Vaccines, COVID19 (disease), United States Food and Drug Administration, Approved, Novavax, Novavax ‘s, Novavax
Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC
Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety
German cancer antibody biotech eyes SPAC as route to Nasdaq
Veraxa, Antibodies, SPAC, German language, Nasdaq